The latest news on osimertinib/Tagressa 2024 medical insurance price

Osimertinib/Osimertinib, formerly known as mereletinib or AZD9291, with the trade name Tagrisso, is a third-generation EGFR TKI drug developed by AstraZeneca Pharmaceuticals for the treatment of mutated EGFR cancer. It is currently the only EGFR TKI approved for patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer. The original drug Osimertinib has entered the scope of Class B medical insurance reimbursement in China. For specific reimbursement conditions and prices, you may need to consult the local medical insurance bureau or hospital.

Osimertinib/ is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) T790M mutations, as first-line treatment for patients whose tumors have EGFR exon 19 deletion or exon 21 L858R mutation; or asEGFR Second-line treatment for patients whose disease has progressed during or after TKI therapy. Osimertinib is a targeted therapy that specifically targets EGFR. By blocking EGFR, osimertinib helps reduce the growth and spread of cancer. Unlike most other tyrosine kinase inhibitors, osimertinib is active against cancer cells harboring the T790M mutation in the EGFR gene.

The common specifications of osimertinib original drug currently on the market in China are80mg*30 tablets , 40mg*30 tablets, etc. The price per box may be around RMB 5,000. The reimbursement conditions are limited to patients who meet the indications, that is, stage IB-IIIA NSCLC patients with EGFR exon 19 deletion or exon 21 (L858R) substitution mutation, and EGFRT790M mutation. The reimbursement ratio is different in different regions, and the price after reimbursement will be different.